Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm prophylaxis study of FRSW107 in previously treated severe hemophilia A
CTR20261141Phase 3Active
- Sponsor
- Kaifeng Pharmaceutical Group Co., Ltd
- Start
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Factor VIII in hemophilia A, sponsored by Kaifeng Pharmaceutical Group Co., Ltd. Started Jun 2026; status: active.
02
Drugs
Factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on CTR20261141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261141.